Management to discuss positive corporate developments and update investors on commercialization pathway during live conference call
SANTA CLARA, Calif., Oct. 14 /PRNewswire-FirstCall/ -- NewCardio, Inc., a cardiac diagnostic and services company, today announced that management will conduct a live teleconference to discuss recent corporate developments and provide an update on the Company's strategy and progress regarding commercialization of its platform technology.
The Company's chairman of the board of directors, Mark Kroll, will moderate the call. He will be joined by Branislav Vajdic, PhD, the Company's Chief Executive Officer, Mr. Vincent Renz, the Company's President and Dr. Ihor Gussak, NewCardio's new Chief Medical Officer.
Anyone interested in participating should call 1-866-933-9780 if calling from the United States, or 503-295-8000 if dialing internationally. A replay will be available until October 28, 2008, which can be accessed by dialing 1-866-415-9493 within the United States and 1-585-419-6446 if dialing internationally. Please use passcode 6263 to access the replay. In addition, the call will be webcast and will be available on the Company's website at www.newcardio.com or by visiting http://app.replayrecorder.com/multipoint/6263 online.
Dr. Vajdic commented, "NewCardio has made tremendous progress in obtaining broad clinical validation for our platform technology, and we are well on our way to achieving commercial success. We have also built a powerful team of proven executives to drive commercialization and further the development of our technology. We believe it is time to provide an update to our shareholders and we look forward to answering questions during the call."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
CONTACT: Investor, Jeff Stanlis, VP of Communications of Hayden
Communications, Inc., +1-602-476-1821, jeff@haydenir.com, for NewCardio,
Inc.
Web site: http://www.newcardio.com/
